Sector News

Oxford regenerative medicine spinout brings on GlaxoSmithKline drug hunter as CSO

September 10, 2018
Life sciences

The University of Oxford’s regenerative drug discovery spinout OxStem Limited has appointed Georg Terstappen as chief scientific officer, to lead development work across its portfolio of six programs that aim to stimulate progenitor and stem cell repair mechanisms within the body.

Most recently, Terstappen served as head of platform technologies and science at GlaxoSmithKline’s R&D center in Shanghai, helping to oversee preclinical drug development. Before that, he headed up discovery biology at AbbVie’s Ludwigshafen, Germany location.

He has also held positions at Bayer, GlaxoWellcome and Siena Biotech, where he was co-founder and CSO.

In addition, Terstappen has held positions at the European Federation of Pharmaceutical Industries and Associations, including vice-chair of the organization’s innovative medicines strategy group, under its public-private Innovative Medicines Initiative. He is also a founding member and co-chair of the IMI’s strategic governing group for neurodegeneration.

OxStem itself acts as a parent holding company, overseeing and funding development of small molecule drugs at a series of subsidiaries, each focused on different therapeutic needs and organ systems. Its current roster includes OxStem Neuro, OxStem Oncology, OxStem Ocular and OxStem Cardio, all of which are in the discovery stage.

Two more branches are being planned: OxStem Immuno, in wound healing and inflammation, and OxStem Beta, targeting the regeneration of insulin-producing beta cells.

Its Neuro outfit is aiming to identify a new class of drugs that stimulate de novo neuron production from neural stem cells to counteract degenerative diseases such as Alzheimer’s.

Similarly, OxStem Cardio hopes to stimulate resident cardiac precursor cells to increase muscle regeneration and improve function following a heart attack, while OxStem Ocular looks to stimulate photoreceptor cell production within the retina.

OxStem Oncology, meanwhile, is looking to develop treatments for a wide range of cancer types, and the “cancer stem-like cells” that can persist after therapy. The company hopes to develop drugs that force those cells to differentiate into more benign states.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.